STOCK TITAN

[144] 10x Genomics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

10x Genomics (TXG) Form 144 notice: The filing reports a proposed sale of 9,228 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $123,747.48, and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired as a Restricted Stock Unit grant on 08/21/2025 totaling 25,785 shares, with payment characterized as services rendered. The filer discloses one prior sale in the last three months: Serge Saxonov sold 9,343 shares on 05/22/2025 for $77,540.36. The notice includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.

Avviso Form 144 di 10x Genomics (TXG): La comunicazione segnala la proposta di vendita di 9.228 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore di mercato complessivo di $123.747,48, con data di vendita approssimativa il 22/08/2025 sulla NASDAQ. I titoli sono stati acquisiti come Restricted Stock Unit (RSU) il 21/08/2025 per un totale di 25.785 azioni, con pagamento classificato come compenso per servizi resi. Il dichiarante riporta una vendita precedente negli ultimi tre mesi: Serge Saxonov ha venduto 9.343 azioni il 22/05/2025 per $77.540,36. L’avviso contiene la dichiarazione obbligatoria che il venditore non è in possesso di informazioni materiali sfavorevoli non divulgate sull’emittente.

Aviso Formulario 144 de 10x Genomics (TXG): La presentación informa de una propuesta de venta de 9.228 acciones ordinarias a través de Morgan Stanley Smith Barney por un valor de mercado agregado de $123.747,48, con fecha aproximada de venta el 22/08/2025 en NASDAQ. Los valores fueron adquiridos como una concesión de Restricted Stock Units (RSU) el 21/08/2025, por un total de 25.785 acciones, con el pago clasificado como servicios prestados. El declarante revela una venta anterior en los últimos tres meses: Serge Saxonov vendió 9.343 acciones el 22/05/2025 por $77.540,36. El aviso incluye la representación exigida de que el vendedor no posee información adversa material no divulgada sobre el emisor.

10x Genomics (TXG) Form 144 통지: 제출서에는 Morgan Stanley Smith Barney를 통해 총 시장가치 $123,747.48에 해당하는 9,228 보통주 매각 제안이 보고되어 있으며, 거래 예상일은 2025-08-22로 NASDAQ에서 진행될 예정입니다. 해당 증권은 제한부 주식(Restricted Stock Unit, RSU)으로 2025-08-21에 취득되었고 총 25,785주이며, 지급 사유는 제공된 서비스에 대한 보수로 분류되어 있습니다. 제출인은 지난 3개월 내에 한 건의 이전 매각을 공개했는데, Serge Saxonov2025-05-229,343주를 $77,540.36에 매각했습니다. 통지서에는 매도인이 발행회사에 관해 미공개의 중요 불리정보를 보유하고 있지 않다는 필수 진술이 포함되어 있습니다.

Avis Formulaire 144 de 10x Genomics (TXG) : Le dépôt signale une proposition de vente de 9 228 actions ordinaires via Morgan Stanley Smith Barney pour une valeur de marché totale de 123 747,48 $, avec une date de vente approximative au 22/08/2025 sur le NASDAQ. Les titres ont été acquis sous forme de Restricted Stock Units (RSU) le 21/08/2025, pour un total de 25 785 actions, le paiement étant qualifié de rémunération pour services rendus. Le déclarant divulgue une vente antérieure au cours des trois derniers mois : Serge Saxonov a vendu 9 343 actions le 22/05/2025 pour 77 540,36 $. L'avis inclut la déclaration requise selon laquelle le vendeur ne détient pas d'informations défavorables matérielles non divulguées concernant l'émetteur.

10x Genomics (TXG) Form 144-Hinweis: Die Einreichung meldet einen vorgeschlagenen Verkauf von 9.228 Stammaktien über Morgan Stanley Smith Barney mit einem aggregierten Marktwert von $123.747,48 und einem voraussichtlichen Verkaufsdatum am 22.08.2025 an der NASDAQ. Die Wertpapiere wurden als Restricted Stock Unit (RSU) am 21.08.2025 erworben und belaufen sich auf insgesamt 25.785 Aktien; die Zahlung ist als für erbrachte Dienstleistungen klassifiziert. Der Melder gibt einen früheren Verkauf in den letzten drei Monaten an: Serge Saxonov verkaufte 9.343 Aktien am 22.05.2025 für $77.540,36. Die Mitteilung enthält die vorgeschriebene Erklärung, dass der Verkäufer keine nicht offen gelegten, wesentlich nachteiligen Informationen über den Emittenten besitzt.

Positive
  • Disclosure completeness: Filing names broker, share counts, acquisition details, prior sale and sale date, meeting Rule 144 requirements
  • Acquisition origin stated: Securities identified as an RSU grant with payment as services rendered, clarifying basis for sale
Negative
  • Insider sale planned: Proposed sale of 9,228 shares (aggregate market value $123,747.48) indicates insider liquidity activity
  • Recent prior sale: Seller reported a sale of 9,343 shares on 05/22/2025 for $77,540.36

Insights

TL;DR: Routine insider notice disclosing an upcoming sale of RSU-derived shares; no earnings or material corporate events included.

The Form 144 documents a proposed sale of 9,228 shares tied to a Restricted Stock Unit grant received one day earlier (08/21/2025). The filing identifies the executing broker and provides the aggregate market value and planned sale date, satisfying Rule 144 disclosure requirements. The presence of a prior sale by the same individual within three months is disclosed. There are no itemized financial results, new contracts, or regulatory actions in this filing to suggest material impact on company fundamentals.

TL;DR: Filing meets insider disclosure standards; shows a recent RSU grant followed by a planned sale and prior recent disposition.

The notice transparently links the securities to a Restricted Stock Unit grant and records the method of payment as services rendered, which clarifies transfer origin. It names the broker, sale amount, and prior sale by Serge Saxonov, fulfilling transparency expectations for insider transactions. This is a compliance-oriented disclosure without governance actions or changes in management disclosed.

Avviso Form 144 di 10x Genomics (TXG): La comunicazione segnala la proposta di vendita di 9.228 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore di mercato complessivo di $123.747,48, con data di vendita approssimativa il 22/08/2025 sulla NASDAQ. I titoli sono stati acquisiti come Restricted Stock Unit (RSU) il 21/08/2025 per un totale di 25.785 azioni, con pagamento classificato come compenso per servizi resi. Il dichiarante riporta una vendita precedente negli ultimi tre mesi: Serge Saxonov ha venduto 9.343 azioni il 22/05/2025 per $77.540,36. L’avviso contiene la dichiarazione obbligatoria che il venditore non è in possesso di informazioni materiali sfavorevoli non divulgate sull’emittente.

Aviso Formulario 144 de 10x Genomics (TXG): La presentación informa de una propuesta de venta de 9.228 acciones ordinarias a través de Morgan Stanley Smith Barney por un valor de mercado agregado de $123.747,48, con fecha aproximada de venta el 22/08/2025 en NASDAQ. Los valores fueron adquiridos como una concesión de Restricted Stock Units (RSU) el 21/08/2025, por un total de 25.785 acciones, con el pago clasificado como servicios prestados. El declarante revela una venta anterior en los últimos tres meses: Serge Saxonov vendió 9.343 acciones el 22/05/2025 por $77.540,36. El aviso incluye la representación exigida de que el vendedor no posee información adversa material no divulgada sobre el emisor.

10x Genomics (TXG) Form 144 통지: 제출서에는 Morgan Stanley Smith Barney를 통해 총 시장가치 $123,747.48에 해당하는 9,228 보통주 매각 제안이 보고되어 있으며, 거래 예상일은 2025-08-22로 NASDAQ에서 진행될 예정입니다. 해당 증권은 제한부 주식(Restricted Stock Unit, RSU)으로 2025-08-21에 취득되었고 총 25,785주이며, 지급 사유는 제공된 서비스에 대한 보수로 분류되어 있습니다. 제출인은 지난 3개월 내에 한 건의 이전 매각을 공개했는데, Serge Saxonov2025-05-229,343주를 $77,540.36에 매각했습니다. 통지서에는 매도인이 발행회사에 관해 미공개의 중요 불리정보를 보유하고 있지 않다는 필수 진술이 포함되어 있습니다.

Avis Formulaire 144 de 10x Genomics (TXG) : Le dépôt signale une proposition de vente de 9 228 actions ordinaires via Morgan Stanley Smith Barney pour une valeur de marché totale de 123 747,48 $, avec une date de vente approximative au 22/08/2025 sur le NASDAQ. Les titres ont été acquis sous forme de Restricted Stock Units (RSU) le 21/08/2025, pour un total de 25 785 actions, le paiement étant qualifié de rémunération pour services rendus. Le déclarant divulgue une vente antérieure au cours des trois derniers mois : Serge Saxonov a vendu 9 343 actions le 22/05/2025 pour 77 540,36 $. L'avis inclut la déclaration requise selon laquelle le vendeur ne détient pas d'informations défavorables matérielles non divulguées concernant l'émetteur.

10x Genomics (TXG) Form 144-Hinweis: Die Einreichung meldet einen vorgeschlagenen Verkauf von 9.228 Stammaktien über Morgan Stanley Smith Barney mit einem aggregierten Marktwert von $123.747,48 und einem voraussichtlichen Verkaufsdatum am 22.08.2025 an der NASDAQ. Die Wertpapiere wurden als Restricted Stock Unit (RSU) am 21.08.2025 erworben und belaufen sich auf insgesamt 25.785 Aktien; die Zahlung ist als für erbrachte Dienstleistungen klassifiziert. Der Melder gibt einen früheren Verkauf in den letzten drei Monaten an: Serge Saxonov verkaufte 9.343 Aktien am 22.05.2025 für $77.540,36. Die Mitteilung enthält die vorgeschriebene Erklärung, dass der Verkäufer keine nicht offen gelegten, wesentlich nachteiligen Informationen über den Emittenten besitzt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TXG Form 144 disclose about the planned sale?

The notice reports a proposed sale of 9,228 common shares via Morgan Stanley Smith Barney, aggregate market value $123,747.48, with an approximate sale date of 08/22/2025 on NASDAQ.

How were the shares being sold acquired?

The securities were acquired as a Restricted Stock Unit grant on 08/21/2025; the filing lists 25,785 shares from that grant and notes payment as services rendered.

Did the filer sell other TXG shares recently?

Yes. The filing discloses a prior sale by Serge Saxonov of 9,343 shares on 05/22/2025, generating gross proceeds of $77,540.36.

Who is the broker handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Services located at 200 W Civic Center Dr., Sandy, UT; the sale is to occur on NASDAQ.

Does the filing state whether the seller has undisclosed material information?

Yes. By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
10X Genomics, Inc.

NASDAQ:TXG

TXG Rankings

TXG Latest News

TXG Latest SEC Filings

TXG Stock Data

1.66B
112.26M
1.87%
105.23%
11.61%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON